Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program

Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas aeruginosa, but its in vitro activity against these isolates and its clinical effectiveness for isolates with MICs of >1 μg/mL is unclear. We investigated the in vitro activity of cefiderocol against P. aeruginosa i...

Descripción completa

Detalles Bibliográficos
Autores principales: Satlin, Michael J., Simner, Patricia J., Slover, Christine M., Yamano, Yoshinori, Nagata, Tsutae D., Portsmouth, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353454/
https://www.ncbi.nlm.nih.gov/pubmed/37347188
http://dx.doi.org/10.1128/aac.00194-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353454/
https://www.ncbi.nlm.nih.gov/pubmed/37347188
http://dx.doi.org/10.1128/aac.00194-23

Ejemplares similares